Top Tweets for #AmyLin
📢#Specialissue: #Peptide-Based Therapeutics: Targeting #Amylin, #Calcitonin, and Related #Receptors
⏰Deadline: 31 October 2026
🎓Guest Editors: Dr. Sangmin Lee and Prof. Dr. Predrag Sikirić
📖Find out more at https://t.co/dUwON9c8AP @MDPIBiologySubj
📢New Review on the Future of Obesity Treatment: Obesity Pharmacotherapy
A research team with participation of Prof. Timo Müller, #HelmholtzMunich, highlights how next-generation therapies targeting #GLP-1, #GIP, #glucagon, and #amylin receptors are reshaping obesity therapy with some treatments achieving more than 20 percent average weight loss alongside improvements in obesity-related comorbidities.
👉To the original publication: https://t.co/69oDCJookJ
@TimoMueller_IDO @ClemmensenC @IDO_Helmholtz @helmholtz_diabc @DiabResearch @uni_copenhagen @novonordisk @EliLillyandCo
#ObesityResearch #MetabolicHealth
New review by Jonas Petersen, @TimoMueller_IDO, @clemmensenc et al.:
“The evolving landscape of obesity pharmacotherapy”
📖 @NatRevDrugDis | 🔗 https://t.co/pjHIKyttE3
👉 A timely overview of next-generation #obesity therapies beyond #GLP1.
And #HFPolaris Ph3 RCT of #zenagamtide in #HFpEF is off the ground 🎉
Excited to deliver keynote on #incretin therapies & zenagamtide, single molecule #Amylin #GLP1 RA w/ trial steering committee co-member Dr Ildiko Lingvay
Stellar kickoff mtg chaired by P Auerbach, E Ola!
The biggest challenge with all #GLP1 therapies is the high rate of gastro- intestinal side effects
#Amylin analog #petrelintide achieved 10.7% weight loss with no cases of vomiting and minimal gastrointestinal adverse events.
This could be the next big thing!
https://t.co/xnRGuRzNMX
Zealand announces + Phase 2 results for #amylin analog #petrelintide which achieved 10.7% weight loss with placebo-like tolerability with NO cases of vomiting and NO treatment discontinuations due to gastrointestinal adverse events.
https://t.co/D0UhLBxutT
This is a comprehensive and timely review of #amylin physiology (and pathophysiology) as well as potential clinical applications relevant to #obesity and #diabetes
👉 https://t.co/CDmJNMKuYf
My takeaways:
- Amylin receptor agonists that are currently in development are not technically "amylin analogues"--this is a crucial distinction because 👇
- Amylin can fibrillate and form islet amyloid polypeptides 🚨Yes, this is analogously concerning as amyloid plaque, but now in the pancreas
- There are 3️⃣ amylin receptors, but amylin can also bind to the calcitonin receptor
- Activating AMY1R or AMY3R will ⬇️food intake and glucose; AMY2R's effective is less known; and calcitonin receptor activation ⬇️ calcium
👉 This means it is crucial that amylin receptor agonist development differentiate themselves based on receptor selectivity and off-target effects
What might make amylin uniquely interesting in #obesity is:
- It ⬇️ bone resorption so that bone density may be protected in the setting of #weightloss
- It might ⬆️ leptin sensitivity (compelling, if you believe in "leptin resistance")
- It ⬆️ the renin-angiotensin-aldosterone system (RAAS)
⭐️ Amylin is getting a makeover. I'm watching this space very closely since the frontrunner, eloralintide, may be clinically effective with a lower risk of side effects
Amylin-based therapies represent a promising option for obesity, offering a potentially more tolerable alternative to current GLP1-based treatments, possibly because of different receptor expression profiles in the hindbrain.
✨New issue✨
Check out the latest in #Metabolism research from across all disciplines.
Read about #AdiposeInnervation, #Amylin, #Cancer, #LiverMetabolism, #MitochondrialMetabolism, #Mycobiome, #Neurometabolism, #Redox, #T2D and many more topics!
https://t.co/i5igWB6pWW
Beyond sema & tirz: a new wave of #GLP1–based drugs is here-dual, triple & oral agents targeting GLP-1, #GIP, #glucagon & #amylin to drive greater #weight ⬇️ & #glycemic control #obesity & #T2D 👉https://t.co/NnSLsspill @DrNadolsky @DrKarlNadolsky @NutritionMadeS3 @DrMarthaGulati
📢#Specialissue: #Peptide-Based Therapeutics: Targeting #Amylin, #Calcitonin, and Related #Receptors
⏰Deadline: 25 May 2026
🎓Guest Editors: Dr. Sangmin Lee and Prof. Dr. Predrag Sikirić
📖Find out more at https://t.co/dUwON9cGqn @MDPIBiologySubj
The @BioCentury show reports that at Obesity Week it was revealed that 30-40% (!) of weight loss with the #amylin class...is from 💪: https://t.co/R7pwN7VWG3
$wve $arwr
On the latest BioCentury This Week podcast: Obesity in Focus: a $10B home for @MetseraInc. And #amylin data, @US_FDA in crisis, and Jim Wilson’s new vision $NVO $PFE w/@StephenPHansen @SteveUsdin @FishburnSimone @LaurenMMartz @Jeff_Cranmer https://t.co/bX1jiNAdqe
.@EliLillyandCo sets the bar for #amylin with #eloralintide weight loss data. Amylin monotherapy shows similar weight loss to market-leading Zepbound tirzepatide at @ObesityWeek #OW2025. @StephenPHansen has the analysis in BioCentury $LLY $MTSR $NVO https://t.co/jRyGU3v3ju
#Eloralintide, a selective #amylin receptor agonist for the treatment of #obesity: a 48-week phase 2, multicentre, double-blind, RCT
Eloralintide (n=263, 48 wks): Dose-dependent weight loss vs placebo: 1 mg −9%, 3 mg −12%, 6 mg −18%, 9 mg −20%, placebo −0.4% (p<0.001). Most common AEs: nausea & fatigue
https://t.co/1Hh4AXyksW
#AMY1R @TheLancet
What’s in the pipeline for #T2D, #adiposity & the multiorgan disorders they cause?
Multi-agonist #incretin-based and #amylin-based synthetic peptides that improve glycaemic control and body weight regulation
#MetabolicSyndrome
https://t.co/PedsDDSvjs
Obesity Drug Design Advanced with Amylin Functional Insights
A newly developed laboratory assay reveals amylin receptor dynamics informing more targeted and effective obesity treatments
@UofOklahoma
#amylin #obesity #drugdevelopment
https://t.co/rPbqeKruQv
🇨🇳 #BrightGene Pharma presented data from two Phase 2 studies for #BGM0504, its investigational dual agonist targeting GLP-1R and GIPR, along with preclinical data for its novel #amylin analog, #BGM1812, #ADA2025. https://t.co/ddascDfMpY
BGM0504 Phase 2 Study in Type 2 Diabetes
Week 12, reductions in HbA1c
-1.72% in the 5mg dose group,
-1.94% in the 10mg dose group,
-2.48% in 15mg dose group,
vs -1.43% in semaglutide and -0.28% in placebo.
BGM0504 Phase 2 Study in Obesity
24-week,
reductions in waist circumference ranging from −8.0 cm to −12.98 cm (p < 0.001),
weight reductions ranging from -10.77% to 19.78% (LS means, placebo adjusted).
improvements in systolic blood pressure ranging from −11.60 to −13.03 mmHg and diastolic blood pressure ranging from −5.98 to −7.50 mmHg (p < 0.05).
BGM1812 Preclinical Study
BGM1812 demonstrated strong receptor activation with 1.8× and 2.2× increased agonist activity (EC50) at the amylin and calcitonin receptors, respectively, versus petrelintide.
Amycretin delivers unprecedented weight loss in early trial for obesity treatment https://t.co/Uzp1LbpBb8 #Amycretin #Obesity #WeightLoss #GLP1 #Amylin #MetabolicHealth #ClinicalTrial #Innovation #Endocrinology #Health @TheLancet
Last Seen Hashtags on Sotwe
countryhumansrussia #countryhumansussr #countryhumansyaoi
Seen from Philippines
incesto hermana
Seen from Panama
soylua
Seen from Argentina
ROBLOXCONDO
Seen from Germany
darlinginthefranxx
Seen from Korea
Fan
Seen from United States
BaddiesGoneWild
Seen from United Kingdom
ometv
Seen from United States
ACFirstCivVP
Seen from United States
pltur
Seen from Turkey
Most Popular Users
Elon Musk 
@elonmusk
240.7M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.8M followers
Taylor Swift
@taylorswift13
81.7M followers
Lady Gaga
@ladygaga
73.2M followers
Virat Kohli
@imvkohli
70.1M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64M followers
Neymar Jr
@neymarjr
62.9M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
60.9M followers
X
@x
60.8M followers